Achillion Pharmaceuticals Inc. (ACHN) announced it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C. The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sovaprevir, ACH-3102, and ribavirin in patients with chronic HCV who have not received prior therapy.
Achillion expects reporting all-oral results from ongoing clinical trials including RVR results from the -007 sovaprevir and ACH-3102 study during the third quarter of current year, as well as providing the updated SVR results later this month from safety and tolerability study of ACH-3102 and ribavirin for the treatment of genotype 1b HCV.
For comments and feedback: editorial@rttnews.com